The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pre-clinical safety and efficacy evaluation of sodium chloride nanoparticles for treating non-muscle invasive bladder cancer.
 
Andrew Gdowski
Employment - Dell Seton Medical Center
 
Lucia Kim
No Relationships to Disclose
 
Xining Lai
No Relationships to Disclose
 
Xinrui Ma
No Relationships to Disclose
 
John Raupp
No Relationships to Disclose
 
Shuyue Zhan
No Relationships to Disclose
 
Wolfgang Beckabir
No Relationships to Disclose
 
Michael Sturdivant
No Relationships to Disclose
 
Sara Elizabeth Wobker
No Relationships to Disclose
 
Zibo Li
Stock and Other Ownership Interests - Athna biotech
 
Jin Xie
No Relationships to Disclose
 
William Y. Kim
Employment - Focal Medical, Inc. (I)
Leadership - Focal Medical, Inc. (I)
Stock and Other Ownership Interests - Abbvie; Abbvie; Amgen; Apellis Pharmaceuticals; Arvinas; Arvinas; BeiGene; Bristol-Myers Squibb; ImmunityBio; Kura Oncology; Lilly; Moderna Therapeutics; Natera; Novo Nordisk; Oramed; Revolution Medicines; Tango Therapeutics; Zentalis
Consulting or Advisory Role - Focal Medical, Inc. (I)
Research Funding - Foundation Medicine; GeneCentric; Merck
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier; PurIST (Purity Independent Subtyping of Tumors) (I)
Other Relationship - Merck